OVERVIEW

What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail is organized by RedMedEd.

Release date: 09/30/2022
Expiration date: 09/30/2023

Overview:
Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative treatment options for patients with MM that has relapsed or become refractory (RRMM) to several lines of therapy.

This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule–based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity.

Learning Objectives:
Upon completion of this activity, participants should be better able to:
• Distinguish between indicated uses, mechanisms of action, and safety profiles of existing and emerging small-molecule therapies and BCMA–targeted immunotherapy for patients who have relapsed from or are resistant to multiple prior therapies
• Evaluate recent clinical advances in the use of small-molecule therapies and BCMA-targeted immunotherapies in patients with RRMM and their potential implications for clinical practice
• Develop individualized management plans for RRMM patients based on patient-, disease-, and treatment-related factors.